Innogen's Global Launch Ceremony Held at Intellective Bio's Changshu Site-Newsroom

On 18 February 2025, the global launch ceremony for Innogen's product was grandly held at Intellective Bio's Changshu site. Leaders from the Changshu Industry and Information Technology Bureau, Innogen and Intellective Bio attended the event and presided over the ribbon-cutting ceremony. The launched product, Yinuoqin^® (Esupaglutide Alfa Injection), is a self-developed innovation by Innogen representing a new generation of fully human ultra-long-acting GLP-1 receptor agonists globally. It has received approval from the National Medical Products Administration for treating adults with Type 2 Diabetes.

Ms. Xu Wenjie, Senior Vice President of Innogen, expressed strong confidence in Yinuoqin^® during her speech, highlighting its excellent performance in glycaemic control and weight reduction. She emphasised the product's globally leading ultra-long half-life (204 hours) and convenient once-weekly dosing regimen that significantly enhances patient compliance. Subsequently, Mr. Xiao Jing, Vice President of Innogen, shared another major announcement that Yinuoqin^® would become available through online platforms starting from 18 February, substantially improving drug accessibility. He further stated that Innogen would work closely with Intellective Bio to jointly establish new benchmarks in the anti-diabetes and weight management therapeutic area.

Mr. Liang, Vice President of Intellective Bio, affirmed in his address the company's full support for Innogen in advancing the production and commercialisation of Yinuoqin®, with a shared commitment to developing high-quality innovative drugs. This collaboration not only demonstrates the effective complementarity of both parties' strengths but also marks a significant step forward for Intellective Bio's commercial manufacturing capabilities.

The successful conclusion of the ribbon-cutting ceremony represented an important milestone for both Innogen and Intellective Bio, while also injecting fresh vitality into Changshu's biopharmaceutical industry and opening a new chapter in innovative drug development and manufacturing.

Looking ahead, Innogen will continue to advance the market expansion of Yinuoqin^® and plans to conduct clinical studies for additional indications, including weight management, metabolic-associated fatty liver disease and Alzheimer's disease. Intellective Bio will continue to leverage its strengths in biopharmaceutical R&D and manufacturing to facilitate the successful development and commercialisation of more innovative therapies.